Mylan in $17.5M deal with Pfizer for generic asthma, COPD products
10 November 2011
Donna Young
Please Login to read the full article.
10 November 2011
Donna Young
donna.young@informa.com
Please Login to read the full article.
RELATED CONTENT
NEWS
- GSK sees £3 billion wiped off value in response to mixed Phase III Relovair data
- GSK has more mixed PhIII Relovair data for COPD, but submissions remain on track
- Does Vectura's US deal on respiratory drug mean FDA is softening on approval pathway?
- Pivotal trials boost Relovair from GSK/ Theravance in COPD
EVENTS
Today
Continental Zara Hotel, Budapest, Hungary
Today
Radisson Blu Royal Hotel, Dublin
Today
Hotel Sofitel Hamburg Alter Wall
JOB OF THE WEEK
Section Head (m/f)
DRA International/CIS Section
Section Head (m/f)
DRA International/CIS Section
